@article{TLCR4245,
author = {Robert Pirker and Martin Filipits},
title = {Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine?},
journal = {Translational Lung Cancer Research},
volume = {4},
number = {6},
year = {2015},
keywords = {},
abstract = {RET fusions have been recognized as potential therapeutic targets in advanced non-small cell lung cancer. RET fusion proteins are detected in about 2% of lung adenocarcinomas. Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. Thus alectinib should be further evaluated within clinical trials in patients with RET fusion-positive adenocarcinomas of the lung.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/4245}
}